Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs RxPros

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and RxPros head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 269 · Grade C

RxPros

Visit RxPros Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 65 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make RxPros a bad call — it's best for readers who can compare the full subscription commitment and obtain the precise formulation and pharmacy before paying. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
36
Supply Reliability
95
80
Transparency
90
72
Access Breadth
93
50
Clinical Oversight
92
84
Track Record
88
78
CoreAge RxBrief Score 94 · 65RxPros

Price, coverage & the tracker

CoreAge RxRxPros
Brief Score94/100 (A)65/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Confirm full selected-term quote

$99.99/month advertisement is paid annually; another section shows $134.99 under introductory or quarterly conditions.

Three-month minimum or selected longer term applies; obtain full first charge and renewal schedule before payment.

Full price details

Compounded semaglutide offered; complete selected-term quote unknown; $99.99/month advertisement is paid annually, while another section shows $134.99/month under introductory or quarterly conditions; minimum commitment and initial invoice require confirmation

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Confirm full selected-term quote

$144.97/month advertisement is paid annually; another section shows $224.99 under introductory or quarterly conditions.

Minimum commitment survives installments; cancellation after prescribing/pharmacy submission is generally final before shipment.

Full price details

Compounded tirzepatide offered; complete selected-term quote unknown; $144.97/month advertisement is paid annually, while another section shows $224.99/month under introductory or quarterly conditions; minimum commitment and initial invoice require confirmation

CoverageUS only; restrictions by state, confirmed at intakeUses U.S. pharmacies and clinical review; complete current medication-specific state eligibility list is not established
Brand-name accessNot confirmedBrand comparison figures do not establish current branded fulfillment through RxPros.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

RxPros: Lowest $99.99/$144.97 monthly equivalents are paid annually; other sections show $134.99/$224.99 with introductory/quarterly conditions. Full selected first charge and renewal term unconfirmed.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.